분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2013-04-17 23:01:25 , Hit : 2147
 BMS, Santaris Make Potentially $100M+ mRNA-Targeting Deal

Apr 16, 2013
(Page 1 of 1)
Bristol-Myers Squibb is teaming up with Santaris Pharma to discover and develop novel medicines using Santaris Pharma's locked nucleic acid (LNA) drug platform. Santaris Pharma is a biopharmaceutical company focused on developing medicines targeted to disease-related mRNAs and microRNAs.

Santaris Pharma will receive an up-front payment of $10 million, up to $90 million in potential milestone payments per product, and funding of ongoing discovery and research activities. In addition, Santaris Pharma will be eligible to receive royalties on the worldwide sales of all medicines arising from the alliance.

The LNA drug platform and drug discovery engine developed by Santaris Pharma combines the company's LNA chemistry with its targeted drug development capabilities to deliver LNA-based drug candidates against RNA targets, both mRNA and microRNA, for a range of diseases including infectious and inflammatory diseases, cardiometabolic disorders, cancer, and rare genetic disorders. The LNA drug platform, according to Santaris, overcomes the limitations of earlier antisense and siRNA technologies to deliver potent single-stranded LNA-based drug candidates across a multitude of disease states.

"We are confident that the unique features of the LNA Drug platform can achieve clinical breakthroughs and look forward to working closely with the Bristol-Myers Squibb team," Henrik Oerum, Ph.D., Santaris Pharma's CSO and vp, business development commented.

Santaris also have an alliance with miRagen Therapeutics going back to June of 2010 to develop microRNA-targeted medicines for the treatment of cardiovascular disease using the LNA drug platform. Back in January of this year, they expanded that alliance, bringing the total number of microRNA targets under the agreement to ten.







727   임자 있는 초원들쥐가 외간들쥐를 거들떠보지도 않는 이유: 후성유전학  이성욱 2013/06/05 3278
726   면역시스템이 유익세균과 평화로운 공존을 유지하는 방법  이성욱 2013/05/28 2492
725   TNF를 이용한 안전한 항종양 치료법  이성욱 2013/05/28 2656
724   Viruses in the gut protect from infection  이성욱 2013/05/22 2907
723   황우석을 넘어서: 미국의 과학자들, 체세포복제 기술로 인간 배아줄기세포 제조 성공  이성욱 2013/05/17 2462
722   Janssen's experimental drug for hepatitis C gets FDA fast track  이성욱 2013/05/15 2827
721   세상을 바꿀 10가지 기술  이성욱 2013/05/13 2329
720   Most Europeans share recent ancestors  이성욱 2013/05/10 2156
719   약물 저항성 세균을 파괴하는 방법  이성욱 2013/05/10 2552
718   분자생물학의 거성(巨星) 떨어지다; 프랑수아 자콥의 삶과 업적  이성욱 2013/05/09 2832
717   FDA fast tracks AbbVie hepatitis C drug  이성욱 2013/05/08 2196
716   Targeted drugs to tackle hepatitis C  이성욱 2013/05/06 1798
715   DNA: Celebrate the unknowns  이성욱 2013/04/26 1971
714   Hepatitis C drug nears approval  이성욱 2013/04/24 2120
713   텔로머레이즈를 표적으로 삼는 새로운 항암 요법  이성욱 2013/04/24 3107
712   A pathogenic picornavirus acquires an envelope by hijacking cellular membranes  이성욱 2013/04/23 3003
  BMS, Santaris Make Potentially $100M+ mRNA-Targeting Deal  이성욱 2013/04/17 2147
710   Scientists Map Elusive 3-D Structure of Telomerase Enzyme, Key Actor in Cancer, Aging  이성욱 2013/04/17 2305
709   Gilead seeks FDA OK for game-changing hepatitis C drug  이성욱 2013/04/10 2114
708   'RNA sponge' mechanism may cause ALS/FTD neurodegeneration  이성욱 2013/04/02 2604

[이전 10개] [1]..[21][22][23][24][25][26][27] 28 [29][30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN